United States Revenue Cycle Management (RCM) Market Outlook to 2030: Size, Share, Growth and Trends

The United States Revenue Cycle Management (RCM) Market is sized at USD 107,500 Mn in 2024 on an industry revenue basis, covering software licenses, SaaS subscriptions, and outsourced or managed RCM services billed to healthcare providers. That scale is credible because it sits inside a healthcare economy that spent USD 5.3 Tn in 2024 and includes very large administrative transaction volumes across eligibility, claims, denials, prior authorization, patient collections, and analytics. The market is therefore not a niche IT category; it is a core operational expenditure layer linked directly to reimbursement execution.

The market is projected to grow from USD 107,500 Mn in 2024 to USD 201,100 Mn by 2030 , implying an 11.0% CAGR during 2025-2030 . This is faster than the modeled 9.0% CAGR during 2019-2024 , which signals a step-up rather than a continuation of historical momentum. Growth is being driven by regulatory API requirements, denial prevention investment, CDI expansion, and rising patient-responsibility workflows. In practical terms, the market’s next phase should be shaped less by simple provider volume growth and more by automation intensity and workflow monetization depth.

The largest current profit pool is Claims & Denial Management , which accounted for USD 26,900 Mn, or 25.0% of total market revenue, in 2024 . This segment remains the largest because claims quality, edits, payer-specific rules, and underpayment recovery all influence realized cash, not just gross charges. The profit pool is also defensible: denial management usually sits close to payer data, historical rules libraries, and workflow configurations that are difficult to replace quickly. That creates strong retention mechanics and supports both software and managed-service monetization.

Clinical Documentation Improvement (CDI) is the fastest-growing segment, with a locked 15.8% CAGR . Its outperformance reflects the fact that documentation quality increasingly determines case mix, coding accuracy, medical necessity support, denial prevention, and audit readiness. CDI also benefits from new AI-assisted abstraction and physician query tools, which raise productivity while linking documentation more directly to reimbursement integrity. As payment models become more scrutiny-heavy, buyers are likely to view CDI less as a coding adjunct and more as an enterprise revenue integrity control point.

The biggest structural risk is concentration risk around transaction infrastructure and cyber resilience. The 2024 Change Healthcare incident showed that a failure at a critical intermediary can immediately hit claims submission, eligibility verification, and provider cash flow. The event was not a temporary inconvenience; it exposed how dependent the market is on interoperable yet concentrated switching layers. For vendors, this raises the cost of resilience, redundancy, and compliance. For providers, it increases the value of diversified connectivity, contingency workflows, and financially stable RCM partners.

The United States is the clear leader among relevant peer markets such as Germany, Canada, the United Kingdom, and Australia. Its advantage is not only healthcare scale, but administrative intensity: a multi-payer system with high denial management, eligibility verification, prior authorization, and patient billing complexity creates a far larger addressable RCM revenue base than peer systems with simpler reimbursement structures. That is why the United States can sustain a market above USD 100 Bn while peer-country markets remain in the single-digit billions. This leadership position should persist through 2030.

The strongest underlying demand driver is the scale of reimbursable healthcare activity combined with persistent administrative burden. In 2024, the U.S. had 6,100 hospitals , 35,658,583 admissions , and USD 5.3 Tn in health expenditure. At the same time, the CAQH Index identified USD 20 Bn of simplification opportunity and the AMA documented heavy prior authorization workloads. This combination means the market has both volume support and productivity headroom. Long-term growth should therefore continue even if provider utilization normalizes, because the efficiency gap remains large.